Ramipril Actavis 1.25 mg Norge - norsk - Statens legemiddelverk

ramipril actavis 1.25 mg

actavis group ptc ehf (1) - ramipril - tablett - 1.25 mg

Ramipril Actavis 2.5 mg Norge - norsk - Statens legemiddelverk

ramipril actavis 2.5 mg

actavis group ptc ehf (1) - ramipril - tablett - 2.5 mg

Ramipril Actavis 10 mg Norge - norsk - Statens legemiddelverk

ramipril actavis 10 mg

actavis group ptc ehf (1) - ramipril - tablett - 10 mg

Valsartan/Hydrochlorthiazid Actavis 80 mg / 12.5 mg Norge - norsk - Statens legemiddelverk

valsartan/hydrochlorthiazid actavis 80 mg / 12.5 mg

actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 80 mg / 12.5 mg

Valsartan/Hydrochlorthiazid Actavis 160 mg / 12.5 mg Norge - norsk - Statens legemiddelverk

valsartan/hydrochlorthiazid actavis 160 mg / 12.5 mg

actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 160 mg / 12.5 mg

Valsartan/Hydrochlorthiazid Actavis 160 mg / 25 mg Norge - norsk - Statens legemiddelverk

valsartan/hydrochlorthiazid actavis 160 mg / 25 mg

actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 160 mg / 25 mg

Valsartan/Hydrochlorthiazid Actavis 320 mg / 12.5 mg Norge - norsk - Statens legemiddelverk

valsartan/hydrochlorthiazid actavis 320 mg / 12.5 mg

actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 320 mg / 12.5 mg

Valsartan/Hydrochlorthiazid Actavis 320 mg / 25 mg Norge - norsk - Statens legemiddelverk

valsartan/hydrochlorthiazid actavis 320 mg / 25 mg

actavis group ptc ehf - valsartan / hydroklortiazid - tablett, filmdrasjert - 320 mg / 25 mg

Pioglitazone Actavis Den europeiske union - norsk - EMA (European Medicines Agency)

pioglitazone actavis

actavis group ptc ehf   - pioglitazonhydroklorid - diabetes mellitus, type 2 - legemidler som brukes i diabetes - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. etter initiering av behandling med pioglitazon, pasienter bør vurderes etter 3 til 6 måneder for å vurdere tilstrekkeligheten av respons på behandling (e. reduksjon i hba1c). hos pasienter som ikke klarer å vise et adekvat svar, pioglitazon bør seponeres. i lys av potensiell risiko med langvarig behandling, prescribers bør bekrefte på følgende rutine anmeldelser dra nytte av pioglitazone er opprettholdt (se kapittel 4.

Rivastigmine Actavis Den europeiske union - norsk - EMA (European Medicines Agency)

rivastigmine actavis

actavis group ptc ehf - rivastigminhydrogentartrat - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - symptomatisk behandling av mild til moderat alvorlig alzheimers demens. symptomatisk behandling av mild til moderat alvorlig demens hos pasienter med parkinsons sykdom.